



ASX RELEASE

11 May 2017

### **Paradigm's Government grant for Ross River virus research**

#### **Key Highlights:**

- Non-dilutive grant from Queensland government to accelerate Ross River virus development
- Alphavirus pre-clinical studies demonstrated pentosan polysulfate sodium (PPS) significantly reduced joint inflammation and protected joint cartilage.

**Paradigm Biopharmaceuticals Ltd (ASX:PAR)** is pleased to announce in collaboration with the Institute of Glycomics at Griffith University that the parties have received a grant of AU\$300,000 from the Queensland government to accelerate the development of PPS to treat Ross River virus.

Paradigm first entered the collaboration with the Institute of Glycomics at Griffith University in September 2016 after preclinical studies, conducted by the Institute, demonstrated that PPS significantly alleviated the severity of alphavirus infections (which include Ross River virus and the related virus, chikungunya) with the key outcome measures being reduced joint inflammation and joint cartilage protection.

By the end of Q2 CY2017, Paradigm is expecting ethics approval and first participant dosing for its Phase 2a clinical trial. The Phase 2a trial will investigate the use of PPS for participants recently infected with Ross River virus. The double-blinded trial will treat 24 clinical trial participants in both Queensland and Victoria.

"The grant from the Queensland government provides important non-dilutive funding so that we can accelerate our Ross River virus biomarker research with the Institute", Paradigm CEO Paul Rennie said.

“Demonstrating, by serum biomarkers, that PPS may protect joint cartilage in people recently infected with Ross River virus is the key reason why the ongoing development program with the Institute is so important”, Mr Rennie added.

Both Paradigm and the Institute wish to thank the Queensland Government for their financial support of this Ross River virus biomarker project.

Paradigm hopes to receive Ethics Approval for its Ross River clinical trial in late May or early June 2017.

Paradigm’s other clinical trials remain on schedule. Hay fever Phase 2 clinical trial read-out of results by end of Q2 CY 2017. Orthopaedic clinical trial (Bone Marrow Edema) read-out of results by end of Q3 CY 2017.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Paul Rennie  
Director & CEO  
Paradigm Biopharmaceuticals Ltd  
Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA  
ABN: 94 169 346 963  
Web: <http://paradigmbiopharma.com/>  
Email: [prennie@paradigmbiopharma.com](mailto:prennie@paradigmbiopharma.com)  
Mobile International: +61 437 778 300  
Mobile (Australia): 0437 778 300